Category Archives: speed resistance line

Review: Lumber Liquidator

As early as February 2015, when the stock price of Lumber Liquidator (LL) was trading at $50, we had indicated that there was a risk that Lumber Liquidator could decline below $23.47.  Since that time, LL had declined as low as $11.

In March 2015, we outlined our own theory of a coincidence indicator that would help investors know when the price of LL should recover.  Since that time, LL has fallen in line with our theory and has subsequently increased in price along with our proposed coincidence indicator.

From the low in LL stock price in 2016, we have seen the stock price climb as much as +200%.  The actual gain based on our recommended purchase price would be approximately +16% (8% annualized) assuming equal share amounts at/or below the recommended levels.

So what does the coincidence indicator say about LL and the prospects going forward?  The chart below is clear on this matter:

Clean Harbors: Coincidence Confirmed, Again

On February 9, 2012, we posted Edson Gould’s Speed Resistance Lines [SRL] regarding Clean Harbors (CLH).  Our hope at the time was that our prior work on the top of Gould’s work would be handily refuted or confirmed.  At the time we posed the following SRL:

For us, our expectation was that the Clean Harbors would, at minimum, descend to the conservative downside target of $43.53.  Well, the timing and coincidence were in our favor as CLH fell –40% to the appointed levels that we thought the stock should descend.

As with all Speed Resistance Lines, there is a chance that the stock will continue to move higher.  However, at each point higher we readjust the SRL and arrive at new downside target.  In the case of CLH, the stock increased from the $67.60 price to as high as $70.30 thereby requiring an adjustment of the downside targets higher as well.  Remember, if the stock does not hit downside targets avoid it.  When and if the stock falls to the target, review for potential investment.

Finally, for no explicable reason, when all seemed in favor of the stock, CLH declined from the $70.30 peak to the low of $37.09 achieved in January 2016.  By achieving such an improbable low (improbable to those who were buying CLH in February 2012) CLH stock price appeared to be worth considering.  For this reason, we iterated a review of CLH for investment consideration on December 14, 2015. Since our mid-December 2015 review, CLH has increased by +39%.


At this point, we’d consider our general analysis of CLH a success from the December 2015 posting.  What do we see going forward?  We see two critical upside resistance levels to watch for.  The first upside resistance is at $59.00 and the second upside resistance level is at $69.00.  Obtaining a +39% gaining in a 1-year period might suggest that an investor consider selling all of their CLH holdings and reinvesting the funds somewhere else.

The Cold Hard Truth

Granted, luck and timing have a lot to say in any and all the work that we produce, however, that does not mean that our efforts on the topic should be dismissed as there may be some value in what we’re trying to accomplish.  Since the very first of our SRLs we’ve had more than 80% of the SRL downside targets achieved at the point of the initial examination.  This generally could could be considered a success.  However, of the 20% that have not been successful are positions that we’ve taken a real world investment in, which totally sucks.

In spite of the prevailing reality we continue to attempt to mitigate the available information with the stocks of interest to us.  We’ll narrow down this situation to a point where the SRL will work and/or we’ll still be able to benefit regardless of whether an immediate rebound is experienced.

Nasdaq Biotechnology ETF

The iShares Nasdaq Biotechnology ETF (IBB) is trading in range that ultimately needs to be resolved.  The outcome is either falling dramatically below $240 or striking the $343 level before doing a retest of the prior high around $400.


Already, IBB has managed to resist falling below the ascending $218.37 level.  This is in defiance of our belief that a highly volatile sector and fund should retest the extreme downside target of $133.60.  Those wanting to have exposure to the biotech sector but unwilling to take on the individual risk should consider the prospects of this ETF.

Nvidia Downside Targets

Below are the downside targets based on the work of Edson Gould and the precedent setting periods from 1999 to the present.

Review: HP Achieves Downside Target and Rebounds

On September 14, 2015, we posted to our site an article about Helmerich & Payne (HP).  At the time we had the following investment conclusion:

“We advise that investors consider HP at the ascending $39.43 level or below.”

HP fell to the level indicated in our posting and has since increased +37% from the article date and +50% from the date of when the stock crossed below the ascending $39.43 level.  Below is the updated Speed Resistance Lines and our perspective on the potential for the stock going forward.